REAL-WORLD TREATMENT PATTERNS IN COMMERCIALLY INSURED PATIENTS WITH RECURRENT OR PROGRESSIVE ENDOMETRIAL CANCER (EC) IN THE USA
Author(s)
Rachel Bhak, MS1, Jing He, PhD1, Neeraj N. Iyer, PhD1, Olayiwola Popoola, PhD1, Audrey Hopkins, PhD1, Murat M. Ikiisik, MD2, Fernanda Musa, MD3;
1Genmab, Princeton, NJ, USA, 2Genmab, Utrecht, Netherlands, 3Providence-Swedish Cancer Institute, Seattle, WA, USA
1Genmab, Princeton, NJ, USA, 2Genmab, Utrecht, Netherlands, 3Providence-Swedish Cancer Institute, Seattle, WA, USA
OBJECTIVES: To describe real-world treatment patterns among patients treated with ≥2 lines of therapy (LOTs) in the advanced EC setting, where the landscape is rapidly evolving.
METHODS: This retrospective observational study used US MarketScan claims data (2018-2024) and included patients with a diagnosis for EC treated with ≥2 LOTs. Treatment regimen distributions and treatment duration were evaluated with descriptive statistics and assessed by LOT.
RESULTS: 646 patients were included. Mean age was 62.3 years, and there was geographic representation across the US: 18.4% in Northeast, 32.0% in Midwest, 37.3% in South, 12.1% in West, and 0.2% unknown. 2L treatment was initiated for 34.8% in 2019-2021 and 65.2% in 2022-2024. Baseline mean (SD) Quan Charlson comorbidity index was 6.7 (1.9), and the most common comorbidities were liver disease (27.4%), diabetes (26.2%), peripheral vascular disease (18.1%), and chronic pulmonary disease (15.2%). 1L treatments consisted largely of platinum-based regimens (with or without an immune checkpoint inhibitor [ICI]; 93.5%), followed by ICI-based regimens without platinum (5.9%). Subsequent treatment regimens were heterogeneous: platinum use decreased by LOT (32.4% of patients in 2L, 21.9% in 3L, and 16.0% in 4L), while nonplatinum chemotherapy use increased (23.1%, 42.7%, and 48.0%, respectively). ICI-containing regimens decreased from 53.3% to 36.0% (2L-4L), with ICI+tyrosine kinase inhibitor combinations comprising about half of these. Treatment duration decreased by LOT: median (IQR) was 4.4 (2.5, 8.2) months in 2L, 3.5 (2.2, 6.5) in 3L, and 3.1 (1.7, 4.3) in 4L.
CONCLUSIONS: In this claims-based dataset of commercially insured patients with recurrent or progressive EC there was considerable comorbidity burden and fragmented 2L+ treatment regimens with limited durability, reflecting the absence of a true/established standard of care. Disease progression is common after ICI exposure. Non-platinum-based chemotherapy remains the principal salvage option despite its limited efficacy, highlighting the need for new, durable treatment options.
METHODS: This retrospective observational study used US MarketScan claims data (2018-2024) and included patients with a diagnosis for EC treated with ≥2 LOTs. Treatment regimen distributions and treatment duration were evaluated with descriptive statistics and assessed by LOT.
RESULTS: 646 patients were included. Mean age was 62.3 years, and there was geographic representation across the US: 18.4% in Northeast, 32.0% in Midwest, 37.3% in South, 12.1% in West, and 0.2% unknown. 2L treatment was initiated for 34.8% in 2019-2021 and 65.2% in 2022-2024. Baseline mean (SD) Quan Charlson comorbidity index was 6.7 (1.9), and the most common comorbidities were liver disease (27.4%), diabetes (26.2%), peripheral vascular disease (18.1%), and chronic pulmonary disease (15.2%). 1L treatments consisted largely of platinum-based regimens (with or without an immune checkpoint inhibitor [ICI]; 93.5%), followed by ICI-based regimens without platinum (5.9%). Subsequent treatment regimens were heterogeneous: platinum use decreased by LOT (32.4% of patients in 2L, 21.9% in 3L, and 16.0% in 4L), while nonplatinum chemotherapy use increased (23.1%, 42.7%, and 48.0%, respectively). ICI-containing regimens decreased from 53.3% to 36.0% (2L-4L), with ICI+tyrosine kinase inhibitor combinations comprising about half of these. Treatment duration decreased by LOT: median (IQR) was 4.4 (2.5, 8.2) months in 2L, 3.5 (2.2, 6.5) in 3L, and 3.1 (1.7, 4.3) in 4L.
CONCLUSIONS: In this claims-based dataset of commercially insured patients with recurrent or progressive EC there was considerable comorbidity burden and fragmented 2L+ treatment regimens with limited durability, reflecting the absence of a true/established standard of care. Disease progression is common after ICI exposure. Non-platinum-based chemotherapy remains the principal salvage option despite its limited efficacy, highlighting the need for new, durable treatment options.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HSD62
Topic
Health Service Delivery & Process of Care
Disease
SDC: Oncology, STA: Biologics & Biosimilars